Pharmacytimes http://www.pharmacytimes.com/rss PharmacyTimes.com offers continuing education (CE) courses, career guidance for pharmacy students, online-only articles, digital versions of the print issue, and more, that are essential to pharmacists en-us Fri, 15 Dec 17 00:55:23 +0000 Fri, 15 Dec 17 00:55:23 +0000 FDA Announces New Tool to Improve Antibiotic Use http://www.pharmacytimes.com/news/fda-announces-new-tool-to-improve-antibiotic-use http://www.pharmacytimes.com/news/fda-announces-new-tool-to-improve-antibiotic-use As part of a larger effort to curb antimicrobial resistance, officials with the FDA have announced a new tool for providing critical information to health care providers about better managing antibiotics and antifungal drugs.<br /> &nbsp; Thu, 14 Dec 17 16:07:00 +0000 Anti-Hypertensive Drug Linked to Increased Skin Cancer Risk? http://www.pharmacytimes.com/news/antihypertensive-drug-linked-to-increased-skin-cancer-risk http://www.pharmacytimes.com/news/antihypertensive-drug-linked-to-increased-skin-cancer-risk A commonly used blood pressure medication may also heighten the risk of developing skin cancer.&nbsp; Thu, 14 Dec 17 15:50:00 +0000 FDA Approves Biologic Drug for Eosinophilic Granulomatosis with Polyangiitis http://www.pharmacytimes.com/product-news/fda-approves-biologic-drug-for-eosinophilic-granulomatosis-with-polyangiitis http://www.pharmacytimes.com/product-news/fda-approves-biologic-drug-for-eosinophilic-granulomatosis-with-polyangiitis Officials with the FDA have approved the expanded use of&nbsp;mepolizumab (Nucala)&nbsp;for the treatment of adults with eosinophilic granulomatosis with polyangiitis (EGPA).&nbsp; Tue, 12 Dec 17 18:38:00 +0000 FDA Gives Final OK to First Short-Acting Follow-On Insulin for Diabetes http://www.pharmacytimes.com/product-news/fda-gives-final-ok-to-first-shortacting-followon-insulin-for-diabetes http://www.pharmacytimes.com/product-news/fda-gives-final-ok-to-first-shortacting-followon-insulin-for-diabetes Officials with the FDA today approved insulin lispro injection (Admelog, Sanofi-Aventis US) 100 units/mL, the first short-acting insulin approved as a follow-on product. Mon, 11 Dec 17 19:17:00 +0000 Generic Viagra Tablets Set to Launch http://www.pharmacytimes.com/product-news/generic-viagra-tablets-set-to-launch http://www.pharmacytimes.com/product-news/generic-viagra-tablets-set-to-launch Teva Pharmaceutical Industries has announced the US launch of their generic sildenafil citrate (Viagra) tablets, according to a company press release.<br /> &nbsp; Mon, 11 Dec 17 13:00:00 +0000 Pharmacists Are Best Suited to Prevent Medication Errors in the Emergency Department http://www.pharmacytimes.com/news/pharmacists-are-best-suited-to-prevent-medication-errors-in-the-emergency-department http://www.pharmacytimes.com/news/pharmacists-are-best-suited-to-prevent-medication-errors-in-the-emergency-department Pharmacists may be the most efficient health care professionals when it comes to preventing medication errors.&nbsp; Fri, 08 Dec 17 15:09:00 +0000 FDA OKs First Nebulized LAMA COPD Treatment http://www.pharmacytimes.com/product-news/fda-oks-first-nebulized-lama-copd-treatment http://www.pharmacytimes.com/product-news/fda-oks-first-nebulized-lama-copd-treatment The FDA has approved glycopyrrolate (Lonhala Magnair, Sunovion) inhalation solution, also known as SUN-101/eFlow, the first nebulized long-acting muscarinic antagonist (LAMA) for the treatment of chronic obstructive pulmonary disease (COPD).<br /> &nbsp; Thu, 07 Dec 17 13:00:00 +0000 FDA Approves Once-Weekly Semaglutide for Type 2 Diabetes http://www.pharmacytimes.com/product-news/fda-approves-onceweekly-semaglutide-for-type-2-diabetes http://www.pharmacytimes.com/product-news/fda-approves-onceweekly-semaglutide-for-type-2-diabetes The FDA has approved Novo Nordisk&rsquo;s semaglutide injection (Ozempic), a glucagon-like peptide 1 (GLP-1) receptor agonist, as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.&nbsp; Tue, 05 Dec 17 19:06:00 +0000 FDA OKs Evolocumab for Prevention of Cardiovascular Events http://www.pharmacytimes.com/product-news/fda-oks-evolocumab-for-prevention-of-cardiovascular-events http://www.pharmacytimes.com/product-news/fda-oks-evolocumab-for-prevention-of-cardiovascular-events The FDA extended the approval of evolocumab (Repatha, Amgen) to include the prophylaxis of heart attacks, strokes, and coronary revascularizations in adults with established heart disease. Mon, 04 Dec 17 19:02:00 +0000 FDA OKs Biosimilar Treatment for Certain Breast and Stomach Cancers http://www.pharmacytimes.com/product-news/fda-oks-biosimilar-treatment-for-certain-breast-and-stomach-cancers http://www.pharmacytimes.com/product-news/fda-oks-biosimilar-treatment-for-certain-breast-and-stomach-cancers The FDA has approved trastuzumab-dkst (Ogivri, Mylan GmbH) as a biosimilar to trastuzumab (Herceptin, Genentech), the first biosimilar for the treatment of certain breast and stomach cancers.<br /> &nbsp; Fri, 01 Dec 17 18:08:00 +0000 Oncology Drug Prices Continue to Rise Despite Market Competition http://www.pharmacytimes.com/news/oncology-drug-prices-on-the-rise-despite-market-competition http://www.pharmacytimes.com/news/oncology-drug-prices-on-the-rise-despite-market-competition Rising cancer drug costs have become inreasingly worrisome for patients and health care providers. Despite the entry of competitors in the market, treatment costs continue to climb over time, according to a study recently published by the&nbsp;Journal of Clinical Oncology.&nbsp; Fri, 01 Dec 17 15:30:00 +0000 FDA Approves Injectable Buprenorphine Treatment for Opioid Use Disorder http://www.pharmacytimes.com/product-news/fda-approves-injectable-buprenorphine-treatment-for-opioid-use-disorder http://www.pharmacytimes.com/product-news/fda-approves-injectable-buprenorphine-treatment-for-opioid-use-disorder The FDA has approved Indivior&rsquo;s Sublocade, the first once-monthly injectable buprenorphine product for the treatment of moderate-to-severe opioid use disorder (OUD). Fri, 01 Dec 17 14:44:00 +0000 FDA OKs Isentress Indication for HIV-1 Exposed Newborns http://www.pharmacytimes.com/product-news/fda-oks-isentress-indication-for-hiv1-exposed-newborns http://www.pharmacytimes.com/product-news/fda-oks-isentress-indication-for-hiv1-exposed-newborns The FDA has extended the approval of raltegravir (Isentress, Merck), an integrase inhibitor for use in combination with other antiretroviral agents, for the treatment of HIV-1 in newborn infants weighing at least 2 kg.&nbsp; Thu, 30 Nov 17 01:00:00 +0000 Are You a Pharmacist and a Mom? http://www.pharmacytimes.com/news/are-you-a-pharmacist-and-a-mom http://www.pharmacytimes.com/news/are-you-a-pharmacist-and-a-mom Currently, more women practice in pharmacy than men, and it is expected that the number of women practicing will continue to rise. Wed, 29 Nov 17 19:55:00 +0000 FDA Warns About Potential Vitamin Interference With Lab Tests http://www.pharmacytimes.com/news/fda-warns-about-potential-vitamin-interference-with-lab-tests http://www.pharmacytimes.com/news/fda-warns-about-potential-vitamin-interference-with-lab-tests The FDA is monitoring reports of adverse events associated with biotin interference with laboratory tests and will update the public if significant new information becomes available. Tue, 28 Nov 17 20:52:00 +0000 Celebrating 45 Years of Pharmacy Stamps http://www.pharmacytimes.com/news/celebrating-45-years-of-pharmacy-stamps http://www.pharmacytimes.com/news/celebrating-45-years-of-pharmacy-stamps This month marks the 45th anniversary of the introduction of the pharmacy stamp. A collector of the commemorative envelopes of first-day covers ruminates on his hobby. Mon, 27 Nov 17 21:30:00 +0000 FDA OKs First Implanted Lens That Can Adjust Following Cataract Surgery http://www.pharmacytimes.com/product-news/fda-oks-first-implanted-lens-that-can-adjust-following-cataract-surgery http://www.pharmacytimes.com/product-news/fda-oks-first-implanted-lens-that-can-adjust-following-cataract-surgery The FDA recommends the device not to be used in patients taking systemic medication that could increase sensitivity to UV light.&nbsp; Wed, 22 Nov 17 19:43:00 +0000 FDA Issues Guidance on Generic Abuse-Deterrent Opioid Development http://www.pharmacytimes.com/product-news/fda-issues-guidance-on-generic-abusedeterrent-opioid-development http://www.pharmacytimes.com/product-news/fda-issues-guidance-on-generic-abusedeterrent-opioid-development Officials with the FDA have released a guidance on the development of generic abuse-deterrent opioids. The final guidance is part of the agency&rsquo;s effort to reduce abuse by decreasing unnecessary exposure to opioids.<br /> &nbsp; Tue, 21 Nov 17 20:56:00 +0000 Pharmacy Times Continuing Education Shows Support for #APharmacistIs Campaign http://www.pharmacytimes.com/news/pharmacy-times-continuing-education-shows-support-for-apharmacistis-campaign http://www.pharmacytimes.com/news/pharmacy-times-continuing-education-shows-support-for-apharmacistis-campaign The <em>Pharmacy Times</em> Continuing Education (PTCE) team recently submitted photos of themselves doing various activities, including running and painting, in support of the #APharmacistIs campaign.&nbsp; Tue, 21 Nov 17 17:21:00 +0000 FDA OKs Epinephrine Auto-Injector for Use in Infants and Small Children http://www.pharmacytimes.com/product-news/fda-oks-epinephrine-autoinjector-for-use-in-infants-and-small-children http://www.pharmacytimes.com/product-news/fda-oks-epinephrine-autoinjector-for-use-in-infants-and-small-children Officials with the FDA have expanded the approval of Kaleo&rsquo;s epinephrine injection, USP (Auvi-Q) to include the treatment of life-threatening allergic reactions in infants and small children. Tue, 21 Nov 17 12:00:00 +0000 FDA Expands Approval of Kidney Cancer Treatment to Recurrence Prevention http://www.pharmacytimes.com/product-news/fda-expands-approval-of-kidney-cancer-treatment-to-recurrence-prevention http://www.pharmacytimes.com/product-news/fda-expands-approval-of-kidney-cancer-treatment-to-recurrence-prevention Officials with the FDA have expanded the approval of sunitinib malate (Sutent, Pfizer) for adjuvant treatment in adult patients who are at high risk of kidney cancer returning after kidney removal.<br /> &nbsp; Fri, 17 Nov 17 21:55:00 +0000 The Role of the Pharmacist in Heart Failure Management http://www.pharmacytimes.com/news/the-role-of-the-pharmacist-in-heart-failure-management http://www.pharmacytimes.com/news/the-role-of-the-pharmacist-in-heart-failure-management In this clip taken at the American Heart Association 2017 Scientific Sessions, Amar Bhakta, MD, from Rush University Medical Center, explains the crucial role that pharmacists play in the management of heart failure. Pharmacists are in a unique position to provide patient education, ensure medication adherence, and assess the patient&#39;s symptoms.&nbsp; Fri, 17 Nov 17 14:38:00 +0000 Team-Based Pathway Prevents Heart Failure Readmissions http://www.pharmacytimes.com/news/teambased-pathway-prevents-heart-failure-readmissions http://www.pharmacytimes.com/news/teambased-pathway-prevents-heart-failure-readmissions In this clip taken at the American Heart Association&#39;s 2017 Scientific Sessions, Amar Bhakta, MD, of Rush University Medical Center, discusses the results from his hospital&#39;s clinical pathway for heart failure, which includes using multidisciplinary teams to prevent and reduce hospital readmissions.&nbsp; Fri, 17 Nov 17 13:00:00 +0000 FDA Approves New Hemophilia A Treatment http://www.pharmacytimes.com/product-news/fda-approves-new-hemophilia-a-treatment http://www.pharmacytimes.com/product-news/fda-approves-new-hemophilia-a-treatment Officials with the FDA have approved emicizumab-kxwh (Hemlibra, Genentech) as a treatment for patients with hemophilia A who have factor VIII inhibitors, according to a press release from the agency.<br /> &nbsp; Thu, 16 Nov 17 21:43:00 +0000 FDA OKs Treatment for Advanced Follicular Lymphoma http://www.pharmacytimes.com/product-news/fda-oks-treatment-for-advanced-follicular-lymphoma http://www.pharmacytimes.com/product-news/fda-oks-treatment-for-advanced-follicular-lymphoma Officials with the FDA have approved&nbsp;obinutuzumab&nbsp;(Gazyva, Genentech) in combination with chemotherapy, followed by obinutuzumab alone, for the first-line treatment of patients with advanced follicular lymphoma, according to the company&#39;s press release.&nbsp; Thu, 16 Nov 17 21:40:00 +0000